QDEL QuidelOrtho Corp

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: global diagnostics provider specializing in immunoassay, molecular testing, clinical chemistry, transfusion medicine, and POC solutions
• • Initiated wind-down of U.S. donor screening portfolio (VIP platform, microplate assays) starting Feb 2024, expected substantially complete by mid-2026
• • New emphasis on advancing digital solutions with launch of QuidelOrtho RESULTS MANAGER and planned 2026 releases of automation and informatics products
• • R&D spend $186.2M in 2025, down from $218.7M in 2024, reflecting project phase transitions and continued innovation investment
• • Customer service innovation highlighted by being first medical device company awarded global ISO Excellence Services Label in EMEA region

Risk Factors

• • Legal/regulatory risk: FDA EUA approvals and compliance with anti-bribery and data privacy laws impacting product commercialization and operations
• • Geopolitical/macro risk: April 2025 U.S. tariffs on imports from U.K., Canada, Mexico, China causing incremental supply chain and shipping costs
• • Operational/supply chain risk: Concentration in California facilities near earthquake/fire faults posing disruption risk to manufacturing and product delivery
• • Competitive risk: Distributors developing own competitive products and exclusive agreements with rivals threatening key sales channels
• • Financial risk: Customer concentration with significant revenues from few distributors; loss would materially disrupt sales and financial results

Management Discussion & Analysis

• • Revenue $2,730.2M FY25, down 2% YoY from $2,782.9M; FY24 down 7% YoY from $2,997.8M, COVID-19 product declines primary driver
• • Operating margin approx. 20.1% FY25 (Operating expenses $1,488.9M = 54.5% of revenue), cost of sales 53.3% vs 53.8% in FY24; margin benefit from cost savings initiatives
• • Best segment growth: EMEA revenue up 7% to $360.7M, Adjusted EBITDA up 78% to $82.6M; worst segment: Donor Screening revenue down 54% to $52.6M due to U.S. wind-down
• • Operating cash flow pressures from restructuring charges: Restructuring charges $263.6M in FY25 vs $127.2M in FY24; buybacks/dividends details not provided; capital spending not detailed
• • Outlook cautious: Ongoing COVID/endemic dynamics, competitive pressures, pricing pressures, geopolitical tariffs risks; restructuring and strategic refocus ongoing to improve financials

What are the latest QDEL SEC filings in 2026?

QuidelOrtho Corp (QDEL) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on June 23, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did QDEL file its most recent 10-K annual report?

QuidelOrtho Corp (QDEL) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view QDEL 10-Q quarterly reports?

QuidelOrtho Corp (QDEL)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every QDEL 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has QDEL filed recently?

QuidelOrtho Corp (QDEL)'s most recent 8-K was filed on June 23, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find QDEL insider trading activity (Form 4)?

SignalX aggregates every QDEL Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does QDEL file with the SEC?

QuidelOrtho Corp (QDEL) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new QDEL filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for QuidelOrtho Corp (QDEL).

What is QDEL's SEC CIK number?

QuidelOrtho Corp (QDEL)'s SEC CIK (Central Index Key) number is 1906324. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1906324 to look up all QDEL filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find QDEL return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from QuidelOrtho Corp (QDEL) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.